Literature DB >> 18241722

Resource utilization in the management of subglottic stenosis.

Rahul K Shah1, Lina Lander, Sukgi S Choi, George H Zalzal.   

Abstract

OBJECTIVE: The purpose of this study was to determine resource utilization in managing subglottic stenosis. STUDY
DESIGN: The Kids' Inpatient Database (KID) 2003 was analyzed. SUBJECTS AND METHODS: International Classification of Diseases, Ninth Revision code 478.74 was the inclusion criteria.
RESULTS: Two thousand forty-six admissions with subglottic stenosis were sampled; there were 10 deaths (0.49%). States with the most admissions were Ohio, California, and Illinois; these did not have the highest spending per admission. Two hundred eighteen (10.7%) underwent a laryngeal graft procedure; states with the most were Ohio (35.8%), Texas, California, and Florida. Indicators of increased resource utilization include length of stay, nonelective admission, race, primary payer, hospital location, and type.
CONCLUSIONS: For subglottic stenosis, three states account for 37% of admissions, and four states account for 56% of laryngeal graft procedures in 2003. The mean total charges were $53,787; 90% of admissions had total charges less than $139,253. Patients who underwent surgical procedures had total charges of $76,409.

Entities:  

Mesh:

Year:  2008        PMID: 18241722     DOI: 10.1016/j.otohns.2007.10.015

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  2 in total

1.  Does influenza vaccination or RSV prophylaxis impact resource utilization for children after the diagnosis of airway disorders?

Authors:  Jeffrey Cheng; Congwen Zhao; Hui-Jie Lee
Journal:  Int J Pediatr Otorhinolaryngol       Date:  2019-02-06       Impact factor: 1.675

2.  Health Care Costs and Cost-effectiveness in Laryngotracheal Stenosis.

Authors:  Linda X Yin; William V Padula; Shekhar Gadkaree; Kevin Motz; Sabrina Rahman; Zachary Predmore; Alexander Gelbard; Alexander T Hillel
Journal:  Otolaryngol Head Neck Surg       Date:  2018-11-27       Impact factor: 3.497

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.